COMMUNIQUÉS West-GlobeNewswire

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
24/09/2025
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to [...]
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France
24/09/2025
H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER 1 and on a like-for-like basis 2 , mainly due to the decline in activity in France Restated EBITDA margin 3 came out at 12.9%, [...]
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387,8 M€, en retrait de 5,4% à TCC et périmètre comparable principalement en lien avec la baisse d’activité en France
24/09/2025
Résultats semestriels 2025 Activité et rentabilité Chiffre d’affaires du 1 er semestre : 387,8 M€, en retrait de 5,4% à TCC 1 et périmètre comparable 2 , principalement en lien avec la baisse d’activité en France La [...]
Eurobio Scientific : résultat du 1er semestre 2025
24/09/2025
RESULTAT DU 1 ER SEMESTRE 2025 Chiffre d’affaires en croissance de 10% à 80,7 M€ les produits propriétaires atteignent 36% du CA la part du CA hors France est de 42% Résultats 2025 impacté par le transfert de la [...]
EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025
24/09/2025
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 million Proprietary products account for 36% of revenue 42% of revenue generated outside France 2025 results impacted by the transfer of [...]
TOMI Environmental Solutions Announces Specialized Service Provider for Healthcare and Mold Remediation
24/09/2025
FREDERICK, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced a new service [...]
Berry Street Earns Recognition from the American Diabetes Association
24/09/2025
The ADA’s Education Recognition Program certification ensures quality diabetes education and support for people living with diabetes. NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Today, the American Diabetes Association [...]
WORK Medical Technology Group LTD Partners with Hong Kong Web3.0 Standardization Association to Collaborate on Blockchain and RWA Innovations
24/09/2025
Hangzhou, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
Alira Health Becomes First Platinum CRO Partner of the Wound Care Collaborative Community, Expanding Ongoing Work to Advance Wound Healing Innovation
24/09/2025
FRAMINGHAM, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Alira Health announced today that it has become the first Platinum CRO Partner of the Wound Care Collaborative Community (WCCC), demonstrating its continued [...]
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
24/09/2025
VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
OneMedNet Expands Into $1.5B Healthcare Data Annotation Market With MedCase
24/09/2025
MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with [...]
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
24/09/2025
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be [...]
Ultrack Systems Inc. (OTC: MJLB) Subsidiary Better Pets Secures Canadian Trademark Registration and Advances U.S. Trademark Application
24/09/2025
TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) (“Ultrack” or the “Company”), through its wholly owned subsidiary Better Pets (Better Health Sciences for Pets Corp.), is pleased to announce [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
24/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano, [...]
Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes
24/09/2025
Funding supports Phase 2b development of clofutriben, a novel HSD-1 inhibitor, with a focus on cortisol-driven metabolic dysfunction in type 2 diabetes PORTLAND, Ore., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sparrow [...]
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
24/09/2025
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Er-Kim Enters Commercialization Agreement with Sentynl Therapeutics for Nulibry® (fosdenopterin) and Zokinvy® (lonafarnib), Targeting Ultra-Rare Diseases
24/09/2025
Expanded access will help bring treatments to patients in certain countries within Central and Eastern Europe, the Mediterranean and Eurasia ATHENS, Greece and SOLANA BEACH, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Er [...]
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
24/09/2025
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“ [...]
Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position
24/09/2025
Expanded microbiology lab and analytical chemistry capabilities position Ritedose for accelerated growth. $17+ million investment fuels innovation and scale in drug development. COLUMBIA, S.C., Sept. 24, 2025 (GLOBE [...]

Pages